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SUMMARY Xanthoma disseminatum is a non-familial disorder of non-Langerhans cell ori-
gin or a class II histiocytosis with unknown etiology, with just over 100 cases reported in 
the literature. Because of the rarity of this disease, there is no established treatment. We 
studied clinical manifestations and different treatments of xanthoma disseminatum from 
a series of cases, including our own patient.  
We studied 15 articles on treatment of xanthoma disseminatum. Local treatment with 
cryotherapy, radiotherapy, surgery, and carbon dioxide lasers have been attempted with 
various results. Systemic medication with peroxisome proliferator-activated gamma recep-
tors, statins, fenofibrate, chlorodeoxyadenosine, cyclophosphamide, doxycycline, and cy-
closporine have also been reported, but none have proven particularly successful. 
Xanthoma disseminatum is usually benign and is often self-limiting. 
If the lesions are accessible to surgery, that is likely to give the best results. However, if the 
lesions are not accessible for surgical removal then carbon dioxide laser treatment may 
be considered. The choice of oral treatment should be made on the basis of the patient’s 
condition, since none of them have proven particularly effective. Expectant management 
is justifiable as long as the lesions are limited to the skin.
KeY woRDS: cyclosporine, doxycycline, histiocytoses, non-Langerhans cell, therapy, xan-
thoma disseminatum
CASe RepoRt
A 61-years old man presented with a two week 
history of pink-brown papules on the trunk and arms. 
He denied any ocular symptoms, dyspnoea, polydip-
sia, polyuria, or neurologic symptoms.
He had taken no medication. No family history of 
a similar skin eruption could be elicited.
On examination there were multiple, round to 
oval, pink-brown papules with size ranging from 0.1 
to 0.5 cm in diameter (Figure 1 and 2) The lesions 
were predominantly located on the upper-back and 
in the abdominal region. Scattered lesions were ob-
served on the arms, and some papules had coalesced 
into small plaques. There was no involvement of the 
oral mucosa. 
Skin biopsy of the lesion revealed a dermal infil-
trate comprising lymphocytes, foamy histiocytes, and 
a few multinuclear giant cells (Figure 3). 
Immunohistochemical analysis revealed positive 
labeling of the histiocytes and multinucleated giant 
cells with antibodies against CD68 (Figure 4). A stain-
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Figure 1. Lesions of xanthoma disseminatum on the 
upper-back of our patient revealing multiple pink-
brown papules, of which some coalesced into small 
plaques.
Figure 2. Close-up of xanthoma disseminatum le-
sions on the upper-back of our patient.
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table 1. Summary of results of systemic treatment and demographic data of patients with xanthoma dissemi-
natum from the published case series and reports
ing with LCA (leucocyte common antigen) was posi-
tive for lymphocytes and histiocytes and negative for 
S-100 and C-KIT markers. Based on the clinical and 
histopathological results we diagnosed xanthoma 
xisseminatum (XD).
Radiographic investigation was performed to ex-
clude any internal manifestation of xanthoma dissem-
inatum that could be fatal. Chest X-ray imaging was 
normal. Computed tomography (CT) investigation of 
the abdomen, on the other hand, revealed multiple 
enlarged lymph nodes in the mesenteric adipose tis-
sue, as well as sigmoid diverticulosis. However, both 
findings were considered to be benign and nonspe-
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Figure 3. Histopathologic features characterized by 
a mixture of lymphocytes, histiocytes, foam cells, and 
several giant cells (C: H&E, ×40).
Figure 4. Immunohistochemical staining positive for 
CD68 in histiocytes and giant cells (D: IHC, ×200).
cific. Single photon emission computed tomography 
(SPECT) / CT bone scans and a nuclear magnetic reso-
nance (NMR) brain scan were both normal. 
Laboratory data revealed hyperthyroidism in novo 
and a pre-existing leukopenia. The levels of choles-
terol, triglycerides, and low density lipoprotein (LDL) 
were all within normal limits. Urinalysis revealed no 
abnormalities. The patient received treatment with 
thiamazol for hyperthyroidism.  
Initial treatment for xanthoma disseminatum 
was doxycycline (200 mg per day). However, after 
one month of observation there was still no sign of 
improvement. Consequently we substituted doxy-
cycline with cyclosporine (300 mg per day) in split 
doses. The treatment was given for six weeks and 
then stopped due to the lack of improvement. We 
then opted for expectant management, since the dis-
ease was tending towards stabilization with no sign 
of new lesions. Approximately five months after the 
onset of the disease, some lesions started to sponta-
neously disappear.
DISCUSSIoN
We reported the case of a 61-years-old man with 
xanthoma disseminatum, who achieved partial re-
mission after subsequent treatments with doxycy-
cline and cyclosporine.
Xanthoma disseminatum (XD) is a non-familial 
disorder of non-Langerhans cell origin or a class II his-
tiocytosis with unknown etiology (1,2). This extreme-
ly rare condition was first described by Montgomery 
and Osterberg in 1938. Only 100 patients had been 
described in the literature to date (2).
The average age of disease onset is over 40 years 
(3). The male to female ratio is 2.4:1 (4).
Primary skin manifestations of XD include multiple 
red-yellow papules and nodules, most commonly in 
the flexural sites. However, large plaques with raised 
and indurated borders and some papules around the 
plaques have also been described by Hisanaga et al. 
(5).
In 40-60% of the patients with XD the mucous 
areas are also infected, which can cause significant 
morbidity and mortality (6). For instance, localized 
mucous lesions in the oropharynx, larynx, and cornea 
can lead to dysphagia, dyspnoea, and obstructive 
blindness respectively (7). If functional anatomic sites 
are not affected by XD lesions, then the natural histo-
ry of this disorder may be benign rather than fatal (6). 
Nonetheless it is important to note that XD does not 
always affect the skin exclusively. At least two case re-
ports described four XD patients with central nervous 
system involvement (8,9). One 23-year-old woman 
died of progressive XD lesions in the brain stem and 
proximal spinal cord. A few cases have also been re-
ported where XD lesions in the pulmonary tract with 
involvement of the small-sized bronchi caused a fatal 
outcome (10,11).
Diabetes insipidus (DI) may also develop as a re-
sult of meningeal lesions in the pituitary fossa. This 
occurs in 40% of the patients (7).
On the basis of the clinical course of the disease, 
three clinical patterns can be distinguished. The per-
sistent form is the most common variant, followed by 
the progressive form with systemic involvement, and 
a self-limited form with spontaneous resolution after 
many years (3). Treatment is symptomatic, and a cura-
tive regimen has not yet been discovered. However, 
experimental medications have been reported to 
cause partial or complete remission in some patients 
(9). 
Many approaches to local treatment of XD have 
been attempted with various results. 
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In the past radiotherapy (RT) of the face and neck 
has been tried to control advancement of the disease 
around the pharynx, larynx, and trachea (12). The ef-
fectiveness of RT is unclear due to the limited number 
of cases. Mahrel et al. found no improvement in an 
adult male with pituitary XD lesions who was treated 
with RT and steroids (13). In another report, cutane-
ous XD lesions in the neck and face region were treat-
ed with no results (14). However, Moloney reported 
one case of successful disease control in a patient 
who received Cobalt RT (15). Alexander et al. con-
cluded in their recent case report that RT has a role in 
palliating local symptoms and in stabilizing disease 
progression when critical structures were involved 
and lesions were not amenable to surgical interven-
tion (16). If the lesions are accessible to surgery then 
it appears to give the best results (3,12). Cryotherapy 
for localized lesions has not been successful (17). In 
a recent case study Carpo et al. achieved excellent 
results with a carbon dioxide (CO2) laser in a 15-year-
old girl with widespread XD lesions (18). The advan-
tages of the CO2 laser are that multiple lesions can be 
treated in one session, which is well tolerated by the 
patient, as well as precise vaporization of lesions and 
minimal postoperative pain and edema. Other treat-
ments of cutaneous lesions include dermabrasion, 
electrocoagulation, and intralesional steroid injec-
tions (18). However, the effectiveness of these thera-
peutic modalities could not be confirmed due to the 
lack of clinical data. 
Use of numerous systemic medications has been 
reported in attempts to manage the disease. Howev-
er, none have proven particularly successful. Table 1 
summarizes the results of published case series. 
A recent case study reported a successful improve-
ment of more than half the lesions using a combina-
tion of three lipid lowering agents: Peroxisome pro-
liferator-activated receptor gamma (PPAR-γ), statins, 
and fenofibrate (19). However, a complete remission 
was never achieved during a follow-up period of 
three years. It is important to note that this patient 
had normal lipid levels, which is commonly found in 
XD patients in contrast to other xanthomatous disor-
ders (19). Similar results with anti-cholesterol drugs 
were supported by two other case reports (20,21).
In one case series report, five patients underwent 
remission of XD lesions after receiving 2-Chlorode-
oxyadenosine (2CdA) treatment. Complete clearance 
of lesions was observed in two patients after a follow-
up period of three and eight years (22).
Seaton et al. proposed cyclophosphamide as a 
potential treatment for the more aggressive form of 
XD, as this resulted in a dramatic resolution of lesions 
in one XD patient with extensive mucocutaneous, oc-
ular laryngeal, pituitary, and central nervous system 
involvement (23).
One case study reported a spectacular improve-
ment and complete clearance of lesions with oral 
doxycycline treatment. (24) After the therapy was 
stopped there was no recurrence in the following six 
months. 
However, the results of the above-mentioned 
case could not be replicated in our patient: there was 
no sign of improvement whatsoever after treating 
the patient with doxycycline for one month. We then 
initiated treatment with cyclosporine. This immu-
nosuppressive agent inhibits T-cell activation and is 
considered to be a potential therapy for systemic ju-
venile xanthogranuloma, which is a non-Langerhans 
cell histiocytosis condition pathologically similar to 
XD (25). Although the lesions still persisted after six 
weeks, the disease tended towards stabilization and 
no other new lesions appeared during the treatment. 
The treatment was then stopped, and we opted for 
an expectant management for the following reasons: 
Firstly, our patient had XD that was only limited to 
cutaneous lesions without systemic involvement and 
thus not life-threatening. Secondly, the lesions tend-
ed towards stabilization during treatment with cy-
closporine. Although cyclosporine may have played 
a role in the recovery, clinical response to treatment 
must be interpreted with caution since XD has the 
potential to stabilize or even undergo spontaneous 
resolution in its natural course, as mentioned before. 
Five months after the onset of the disease lesions 
started to disappear. which led us to conclude that 
our patient had most likely suffered the self-limited 
form of XD, which may be affected by cyclosporine. 
CoNCLUSIoN
In this article, we presented our experience with 
cyclosporine in the treatment of XD. We believe that 
if the lesions are accessible to surgery, then surgery 
probably constitutes the best treatment. However, 
if the lesions are too extensive for surgical removal, 
then a CO2 laser can be considered. We believe that 
expectant management is justifiable in XD patients 
as long as the lesions are limited to the skin and do 
not affect vulnerable mucous areas or internal organs 
that can be potentially life-threatening. Nevertheless, 
XD is usually benign and is often self-limiting. 
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